New Patent For Ampliphi Biosciences Corp. (NYSEMKT:APHB) Is A Major Catalyst


Ampliphi Biosciences Corp. (NYSEMKT: APHB) was recently awarded a potentially transformative patent covering the area of bacterial resistance to antibiotic treatments. The company has come up with phage cocktails that could reinvigorate antibiotics that may have long been thought of as obsolete. The European patent office granted Ampliphi patent No. 2136826, which covers the beneficial effects associated with bacteriophage treatments.

Ampliphi Biosciences Corp. (NYSEMKT: APHB), whose domain is developing therapies for treating drug-resistant infections, said that the Australian patent office had also granted it a patent corresponding to the one granted in Europe. The company further disclosed that the U.S. patent office had issued it with a species-specific patent for phage treatment in the case of Pseudomonas aeruginosa infection.

Ampliphi hopes that its intellectual property portfolio will continue to expand in the coming months as it has other patents pending in the U.S., Canada and Japan.

Resistance to antibiotics

Ampliphi Biosciences Corp. (NYSEMKT: APHB)’s phage formulation is designed in such a way that it tricks bacterial to behave in certain way after the first antibiotic treatment so that they become vulnerable when they encounter the same antibiotic another time. The company said that its phage formulation offers hope to make some antibiotics previously thought of as obsolete relevant again.

As such, Ampliphi is in the process of evaluating various legacy and current antibiotics with its proprietary phage formulation with an aim of reinvigorating them to combat the threat of antibiotic resistance.

There is currently a global concern over the rise of antibiotic resistance in the treatment of bacterial infections. As such, Ampliphi’s cocktails could offer great hope to the medical community and millions of patients on antibiotics globally.

Ampliphi Biosciences Corp. (NYSEMKT: APHB) raises additional capital

As part of its efforts to continue developing solutions to counter the threat of antibiotic resistance, Ampliphi Biosciences Corp (NYSEMKT: APHB) recently raised additional capital through securities offering that included equity. The company sold more than 2.1 million shares of its common stock directly and granted purchasers of those shares warrants to purchase additional shares of its common stock totaling about 1 million.

Ampliphi expected to raise net proceeds of $4.5 million through the securities officering and said the money would be used for general corporate purposes including working capital.


Leave A Reply